跳至主要内容
临床试验/NCT01740934
NCT01740934已完成不适用

An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Subjects With Rosacea Followed by an Open-Label Extension

Rock Creek Pharmaceuticals, Inc.6 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2012年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
117
试验地点
6
主要终点
Adverse Effects

研究概览

简要总结

This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age between 25-70 years
  • diagnosed with mild to moderate rosacea

排除标准

  • allergy or sensitivity to the study products or their components
  • severe rosacea
  • current use of glucocorticoids, anti-acne products, antibiotics, topical retinoids, or vasoactive drugs
  • recent oral isotretinoin use
  • current use of anatabine-containing supplements (ie. Anatabloc, Anatabloc Unflavored, CigRx)

结局指标

主要结局

Adverse Effects

时间窗: 8 to 16 weeks

Collected information of the safety, tolerability and adverse events, and subjective experience related to the use of Anatabloc Cream by subjects

次要结局

  • Change in the appearance of the facial skin(8 to 16 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

A Study to Evaluate the Safety, Tolerability, and... | 临床试验